Alicia Tyson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Alicia Tyson has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Annemarei Ranta
Department of Medicine, University of Otago, Wellington, New Zealand
4 shared publications - Peter Alan Barber
University of Auckland
2 shared publications Abhishek Ranjan
Department of Neurology (I.M.S., C.M., A.H.S., A.L.S.T., M.M.P., A.R.), Wellington Hospital, Wellington, New Zealand; Wellington Free Ambulance (A.H.S., M.G.M., M.C.H.), Wellington, New Zealand; and 3Department of Medicine (A.R.), University of Otago, Wellington, New Zealand
1 shared publicationAdnan Mujanovic
1 shared publicationAdrian Scutelnic
1 shared publication- Alan Davis
National Stroke Network
1 shared publication
Latest Publications
- Open Access
- 15 September 2026
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
Ethnic Differences in Outcomes of Endovascular Thrombectomy in New Zealand
Introduction: Stroke is a leading cause of morbidity and mortality in New Zealand, with ethnic disparities known to exist. Endovascular thrombectomy (EVT) has proven efficacy in reducing or preventing disability for stroke patients, but little is known about ethnic differences in functional outcomes following EVT in New Zealand. Methods: A retrospective nationwide registry‐based study was conducted, including all patients who underwent EVT between 1st January 2011 through to 31st December 2023 in New Zealand. Demographic, clinical and procedural data were obtained from the National Stroke Register. Primary outcomes were mortality at 7 days and dichotomised modified Rankin Scale (mRS) at 90 days. Subgroup analysis compared patients presenting directly to EVT‐capable centres with those requiring transfer. Results: 2852 EVT patients were included (68.7% European, 14.6% Māori, 7.4% Pacific, 8.4% Asian and 1.0% Other). Non‐Europeans presented at younger ages and with greater vascular risk factors. Functional outcomes and 7‐day mortality rates did not differ significantly by ethnicity. Odds of symptomatic intracranial haemorrhage (sICH) were greater in Māori (aOR 3.01, 1.42–6.38, p = 0.004), Pacific peoples (3.40, 1.22–9.53, p = 0.02) and Asian (aOR 3.57, 1.57–8.15, p = 0.002) patients compared to Europeans. Nearly half of patients (46.5%) initially presented to non‐EVT capable centres; although EVT was delayed, functional and mortality outcomes remained similar. Conclusion: This nationwide study found no significant ethnic disparities in functional outcomes or 7‐day mortality following EVT, though sICH was more likely in non‐Europeans. Despite treatment delays, patients initially presenting to non‐EVT capable centres achieved comparable functional outcomes to those presenting directly to EVT centres.
- 15 September 2026
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
Open AccessEthnic Differences in Outcomes of Endovascular Thrombectomy in New Zealand
Introduction: Stroke is a leading cause of morbidity and mortality in New Zealand, with ethnic disparities known to exist. Endovascular thrombectomy (EVT) has proven efficacy in reducing or preventing disability for stroke patients, but little is known about ethnic differences in functional outcomes following EVT in New Zealand. Methods: A retrospective nationwide registry‐based study was conducted, including all patients who underwent EVT between 1st January 2011 through to 31st December 2023 in New Zealand. Demographic, clinical and procedural data were obtained from the National Stroke Register. Primary outcomes were mortality at 7 days and dichotomised modified Rankin Scale (mRS) at 90 days. Subgroup analysis compared patients presenting directly to EVT‐capable centres with those requiring transfer. Results: 2852 EVT patients were included (68.7% European, 14.6% Māori, 7.4% Pacific, 8.4% Asian and 1.0% Other). Non‐Europeans presented at younger ages and with greater vascular risk factors. Functional outcomes and 7‐day mortality rates did not differ significantly by ethnicity. Odds of symptomatic intracranial haemorrhage (sICH) were greater in Māori (aOR 3.01, 1.42–6.38, p = 0.004), Pacific peoples (3.40, 1.22–9.53, p = 0.02) and Asian (aOR 3.57, 1.57–8.15, p = 0.002) patients compared to Europeans. Nearly half of patients (46.5%) initially presented to non‐EVT capable centres; although EVT was delayed, functional and mortality outcomes remained similar. Conclusion: This nationwide study found no significant ethnic disparities in functional outcomes or 7‐day mortality following EVT, though sICH was more likely in non‐Europeans. Despite treatment delays, patients initially presenting to non‐EVT capable centres achieved comparable functional outcomes to those presenting directly to EVT centres.
- Open Access
- 1 July 2026
- Published by BMJ in BMJ Neurology Open
- Vol. 8 (2) , e001704
Stroke reperfusion in Aotearoa New Zealand: 5-year trends and a comparison of stroke clot retrieval and non-stroke clot retrieval centre presenters
Background: Intravenous thrombolysis (IVT) and stroke clot retrieval (SCR) are effective stroke reperfusion treatments with historical underuse and reported access disparities. Aims: This study describes trends in stroke reperfusion treatment between 2020 and 2024 in New Zealand and compares outcomes between patients first presenting to SCR and non-SCR centres. Methods: This observational registry-study uses data from the National Stroke Register for patients receiving reperfusion therapy. Outcomes include treatment rates, time delays, mortality and complications. Results: In 2020, 1021 of 7333 (13.9%) patients who had an ischaemic stroke had reperfusion therapy, increasing to 1237 of 6867 (18.0%) in 2024 (p<0.001). The greatest increases in therapy rates were among non-SCR centre first presenters. IVT rates increased from 11.2% in 2020 to 12.4% in 2024 (p=0.038), with reduced rates of symptomatic intracranial haemorrhage (3.2% to 1.5%; p=0.0272) and day-7 mortality (8.5% to 5.6%; p<0.001). SCR rates increased from 5.3% in 2020 to 9.7% in 2024 (p<0.001), with no change in patient outcomes. Between 2020 and 2024, national median door-to-needle time increased from 60 to 74 min (p<0.001). Patients first presenting to SCR centres were more likely to be treated with IVT within 60 min (48.4% vs 31.7%; p<0.001; adjusted OR of 2.8 (95% CI 2.0 to 4.0)). Conclusion: New Zealand stroke reperfusion therapy rates are rising, especially at non-SCR centres, and outcomes following IVT are improving. IVT treatment delays are worsening suggesting more resources are needed to maintain workflow efficiencies as case complexity is rising.
- 1 July 2026
- Published by BMJ in BMJ Neurology Open
- Vol. 8 (2) , e001704
Open AccessStroke reperfusion in Aotearoa New Zealand: 5-year trends and a comparison of stroke clot retrieval and non-stroke clot retrieval centre presenters
Background: Intravenous thrombolysis (IVT) and stroke clot retrieval (SCR) are effective stroke reperfusion treatments with historical underuse and reported access disparities. Aims: This study describes trends in stroke reperfusion treatment between 2020 and 2024 in New Zealand and compares outcomes between patients first presenting to SCR and non-SCR centres. Methods: This observational registry-study uses data from the National Stroke Register for patients receiving reperfusion therapy. Outcomes include treatment rates, time delays, mortality and complications. Results: In 2020, 1021 of 7333 (13.9%) patients who had an ischaemic stroke had reperfusion therapy, increasing to 1237 of 6867 (18.0%) in 2024 (p<0.001). The greatest increases in therapy rates were among non-SCR centre first presenters. IVT rates increased from 11.2% in 2020 to 12.4% in 2024 (p=0.038), with reduced rates of symptomatic intracranial haemorrhage (3.2% to 1.5%; p=0.0272) and day-7 mortality (8.5% to 5.6%; p<0.001). SCR rates increased from 5.3% in 2020 to 9.7% in 2024 (p<0.001), with no change in patient outcomes. Between 2020 and 2024, national median door-to-needle time increased from 60 to 74 min (p<0.001). Patients first presenting to SCR centres were more likely to be treated with IVT within 60 min (48.4% vs 31.7%; p<0.001; adjusted OR of 2.8 (95% CI 2.0 to 4.0)). Conclusion: New Zealand stroke reperfusion therapy rates are rising, especially at non-SCR centres, and outcomes following IVT are improving. IVT treatment delays are worsening suggesting more resources are needed to maintain workflow efficiencies as case complexity is rising.
- 1 October 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (10) , 2836-2845
Intravenous Thrombolysis in Patients With Recent Intake of Direct Oral Anticoagulants: A Target Trial Analysis and Comparison With Reversal Agent Use
BACKGROUND: Intravenous thrombolysis (IVT) in patients with recent ingestion of direct oral anticoagulants (DOACs) is a frequent challenge and remains controversial. The benefit of DOAC reversal before IVT is uncertain. METHODS: Using target trial methodology, we analyzed data from 28 comprehensive stroke centers. Patients on DOACs were included if they met IVT criteria, had a National Institutes of Health Stroke Scale score of ≥2, and last DOAC intake within 48 hours or was undeterminable. Safety and efficacy outcomes (symptomatic intracerebral hemorrhage, any intracerebral hemorrhage, major bleeding, 90-day mortality, and good functional outcome [modified Rankin Scale score of 0–2 or return to baseline]) were compared between those receiving IVT versus no IVT and IVT with versus without reversal. In addition, a comparison was made with patients from the New Zealand stroke registry, all of whom underwent reversal with idarucizumab. We adjusted for covariates known to be associated with safety and efficacy outcomes, including age, stroke severity, intended thrombectomy, blood glucose, blood pressure, DOAC reversal, and time from last intake. RESULTS: Overall, 1342 patients fulfilled the target trial criteria. The median age was 80 (interquartile range, 73–86) years, median National Institutes of Health Stroke Scale score was 11, 50% were female, and 52% of patients received endovascular therapy. IVT was given in 342 of 1342 (25%) patients. Of these, 141 (41.2%) had verified DOAC intake <12 hours before admission, and 92 (26.9%) within 12 to 24 hours. Symptomatic intracerebral hemorrhage occurred in 10 of 328 (3.0%) of patients receiving IVT and 54 of 921 (5.9%) patients not receiving IVT (adjusted difference, −2.1% [95% CI, −5.3% to +1.2]). Patients receiving IVT were more likely to have good functional outcomes (adjusted difference, +14.4% [95% CI, +7.1% to +21.8%]). Comparing 289 patients with reversal (from the additional New Zealand registry) and 283 patients without reversal before IVT (from the target trial population), there was no significant difference in symptomatic intracerebral hemorrhage, major bleeding, or efficacy outcomes. CONCLUSIONS: This target trial confirms previous observational data regarding the safety of off-label IVT in patients with recent DOAC intake. More data and dedicated trials are needed for patients with confirmed high DOAC plasma levels and regarding the efficacy and safety of DOAC reversal before IVT.
- 1 October 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (10) , 2836-2845
Intravenous Thrombolysis in Patients With Recent Intake of Direct Oral Anticoagulants: A Target Trial Analysis and Comparison With Reversal Agent Use
BACKGROUND: Intravenous thrombolysis (IVT) in patients with recent ingestion of direct oral anticoagulants (DOACs) is a frequent challenge and remains controversial. The benefit of DOAC reversal before IVT is uncertain. METHODS: Using target trial methodology, we analyzed data from 28 comprehensive stroke centers. Patients on DOACs were included if they met IVT criteria, had a National Institutes of Health Stroke Scale score of ≥2, and last DOAC intake within 48 hours or was undeterminable. Safety and efficacy outcomes (symptomatic intracerebral hemorrhage, any intracerebral hemorrhage, major bleeding, 90-day mortality, and good functional outcome [modified Rankin Scale score of 0–2 or return to baseline]) were compared between those receiving IVT versus no IVT and IVT with versus without reversal. In addition, a comparison was made with patients from the New Zealand stroke registry, all of whom underwent reversal with idarucizumab. We adjusted for covariates known to be associated with safety and efficacy outcomes, including age, stroke severity, intended thrombectomy, blood glucose, blood pressure, DOAC reversal, and time from last intake. RESULTS: Overall, 1342 patients fulfilled the target trial criteria. The median age was 80 (interquartile range, 73–86) years, median National Institutes of Health Stroke Scale score was 11, 50% were female, and 52% of patients received endovascular therapy. IVT was given in 342 of 1342 (25%) patients. Of these, 141 (41.2%) had verified DOAC intake <12 hours before admission, and 92 (26.9%) within 12 to 24 hours. Symptomatic intracerebral hemorrhage occurred in 10 of 328 (3.0%) of patients receiving IVT and 54 of 921 (5.9%) patients not receiving IVT (adjusted difference, −2.1% [95% CI, −5.3% to +1.2]). Patients receiving IVT were more likely to have good functional outcomes (adjusted difference, +14.4% [95% CI, +7.1% to +21.8%]). Comparing 289 patients with reversal (from the additional New Zealand registry) and 283 patients without reversal before IVT (from the target trial population), there was no significant difference in symptomatic intracerebral hemorrhage, major bleeding, or efficacy outcomes. CONCLUSIONS: This target trial confirms previous observational data regarding the safety of off-label IVT in patients with recent DOAC intake. More data and dedicated trials are needed for patients with confirmed high DOAC plasma levels and regarding the efficacy and safety of DOAC reversal before IVT.
- 8 November 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 99 (19) , E2125-E2136
Prehospital Telestroke vs Paramedic Scores to Accurately Identify Stroke Reperfusion Candidates
Background: Stroke reperfusion therapy is time critical. Improving pre-hospital diagnostic accuracy including the likelihood of large vessel occlusion can aid with efficient and appropriate diversion decisions to optimise onset-to-treatment time. Objective: To investigate whether pre-hospital telestroke improves diagnostic accuracy when compared with paramedic assessments and to assess feasibility. Methods: We conducted a pragmatic, community-based, cluster randomised controlled trial comparing the diagnostic accuracy of telestroke assessments inside the ambulance to a modified Los Angeles Motor Scale (PASTA score. The primary outcome was the accuracy of predicting reperfusion candidates; secondary outcomes were accuracy, sensitivity, specificity, positive, and negative predictive values of either approach to identify intravenous thrombolysis (IVT) and endovascular thrombectomy (EVT) candidates, and true stroke patients by study group. The accuracy of telestroke and PASTA assessments were compared against in-person assessment in the emergency department and to the final diagnosis/intervention for the patient. We also monitored for technical challenges. Results: We recruited 76 patients (35 telestroke; 41 PASTA), between August 2019 and September 2020. Mean age was 72.2 (+/-14.6) years. Telestroke was 100% (95% CI 90-100%) and PASTA 70.7% (54.5-83.9%) accurate in predicting reperfusion candidates compared to pre-imaging emergency department neurologist assessment (ppp p=0.005). The service model proved technically feasible and was acceptable to neurologists. Conclusion: Pre-hospital telestroke assessment is feasible, accurate, and superior to the PASTA score in predicting acute reperfusion therapies presenting an effective option to guide pre-hospital diversion decisions. Trial Registration: The trial was registered with the Australian and New Zealand Clinical Trials Registry (ACTRN12619001678189). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=378655&isReview=true Classification of Evidence: This study provides Class I evidence that intra-ambulance telestroke evaluation has greater diagnostic accuracy compared to the PASTA score performed by paramedics in distinguishing hyperacute stroke patients who are candidates for reperfusion therapy.
- 8 November 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 99 (19) , E2125-E2136
Prehospital Telestroke vs Paramedic Scores to Accurately Identify Stroke Reperfusion Candidates
Background: Stroke reperfusion therapy is time critical. Improving pre-hospital diagnostic accuracy including the likelihood of large vessel occlusion can aid with efficient and appropriate diversion decisions to optimise onset-to-treatment time. Objective: To investigate whether pre-hospital telestroke improves diagnostic accuracy when compared with paramedic assessments and to assess feasibility. Methods: We conducted a pragmatic, community-based, cluster randomised controlled trial comparing the diagnostic accuracy of telestroke assessments inside the ambulance to a modified Los Angeles Motor Scale (PASTA score. The primary outcome was the accuracy of predicting reperfusion candidates; secondary outcomes were accuracy, sensitivity, specificity, positive, and negative predictive values of either approach to identify intravenous thrombolysis (IVT) and endovascular thrombectomy (EVT) candidates, and true stroke patients by study group. The accuracy of telestroke and PASTA assessments were compared against in-person assessment in the emergency department and to the final diagnosis/intervention for the patient. We also monitored for technical challenges. Results: We recruited 76 patients (35 telestroke; 41 PASTA), between August 2019 and September 2020. Mean age was 72.2 (+/-14.6) years. Telestroke was 100% (95% CI 90-100%) and PASTA 70.7% (54.5-83.9%) accurate in predicting reperfusion candidates compared to pre-imaging emergency department neurologist assessment (ppp p=0.005). The service model proved technically feasible and was acceptable to neurologists. Conclusion: Pre-hospital telestroke assessment is feasible, accurate, and superior to the PASTA score in predicting acute reperfusion therapies presenting an effective option to guide pre-hospital diversion decisions. Trial Registration: The trial was registered with the Australian and New Zealand Clinical Trials Registry (ACTRN12619001678189). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=378655&isReview=true Classification of Evidence: This study provides Class I evidence that intra-ambulance telestroke evaluation has greater diagnostic accuracy compared to the PASTA score performed by paramedics in distinguishing hyperacute stroke patients who are candidates for reperfusion therapy.
- 1 October 2021
- Published by Wolters Kluwer Health in Stroke
- Vol. 52 (10) , E590-E593
Switching to Tenecteplase for Stroke Thrombolysis
Background and Purpose: Due to practical advantages, increasing trial safety data, recent Australian Guideline endorsement and local population needs we switched to tenecteplase for stroke thrombolysis from alteplase. We describe our change process and real-world outcome data. Methods: Mixed-methods including stakeholder engagement, preimplementation and postimplementation surveys, and assessment of patient treatment rates, metrics, and clinical outcomes preimplementation and postimplementation adjusting regression analyses for age, sex, National Institutes of Health Stroke Scale, premorbid modified Rankin Scale score, and thrombectomy using New Zealand National Stroke Registry data. Results: Preswitch consultation involved stroke and emergency clinicians, pharmacists, national regulatory bodies, and hospital legal teams. All survey responders (90% response rate) supported the proposed change and remained satisfied 12 months postimplementation. Between January 2018 and February 2021, we treated 555 patients with alteplase and 283 with tenecteplase. Patients treated with tenecteplase had greater odds of a favorable modified Rankin Scale using both shift (adjusted odds ratio, 1.60 [95% CI, 1.15–2.22]) and dichotomous analyses (modified Rankin Scale score, 0–2; adjusted odds ratio, 2.17 [95% CI, 1.31–3.59]) and shorter median (interquartile range) door-to-needle time (median, 53 [38–73.5] versus 61 minutes [45–85], P =0.0002). Symptomatic intracranial hemorrhage rates (tenecteplase 1.8% versus 3.4%; adjusted odds ratio, 0.46 [95% CI, 0.13–1.64]), death by day 7 (tenecteplase 7.5% versus 11.8%; adjusted odds ratio, 0.46 [95% CI, 0.21–0.99]), and median (interquartile range) needle to groin time for the 42 transferred regional patients (tenecteplase 155 [113–248] versus 200 [158–266]; P =0.27) did not significantly differ. Conclusions: Following stakeholder endorsement, a region-wide switch from alteplase to tenecteplase was successfully implemented. We found evidence of benefit and no evidence of harm.
- 1 October 2021
- Published by Wolters Kluwer Health in Stroke
- Vol. 52 (10) , E590-E593
Switching to Tenecteplase for Stroke Thrombolysis
Background and Purpose: Due to practical advantages, increasing trial safety data, recent Australian Guideline endorsement and local population needs we switched to tenecteplase for stroke thrombolysis from alteplase. We describe our change process and real-world outcome data. Methods: Mixed-methods including stakeholder engagement, preimplementation and postimplementation surveys, and assessment of patient treatment rates, metrics, and clinical outcomes preimplementation and postimplementation adjusting regression analyses for age, sex, National Institutes of Health Stroke Scale, premorbid modified Rankin Scale score, and thrombectomy using New Zealand National Stroke Registry data. Results: Preswitch consultation involved stroke and emergency clinicians, pharmacists, national regulatory bodies, and hospital legal teams. All survey responders (90% response rate) supported the proposed change and remained satisfied 12 months postimplementation. Between January 2018 and February 2021, we treated 555 patients with alteplase and 283 with tenecteplase. Patients treated with tenecteplase had greater odds of a favorable modified Rankin Scale using both shift (adjusted odds ratio, 1.60 [95% CI, 1.15–2.22]) and dichotomous analyses (modified Rankin Scale score, 0–2; adjusted odds ratio, 2.17 [95% CI, 1.31–3.59]) and shorter median (interquartile range) door-to-needle time (median, 53 [38–73.5] versus 61 minutes [45–85], P =0.0002). Symptomatic intracranial hemorrhage rates (tenecteplase 1.8% versus 3.4%; adjusted odds ratio, 0.46 [95% CI, 0.13–1.64]), death by day 7 (tenecteplase 7.5% versus 11.8%; adjusted odds ratio, 0.46 [95% CI, 0.21–0.99]), and median (interquartile range) needle to groin time for the 42 transferred regional patients (tenecteplase 155 [113–248] versus 200 [158–266]; P =0.27) did not significantly differ. Conclusions: Following stakeholder endorsement, a region-wide switch from alteplase to tenecteplase was successfully implemented. We found evidence of benefit and no evidence of harm.